Relmada Therapeutics (RLMD) Amortizatization of Intangibles (2014 - 2019)
Relmada Therapeutics (RLMD) posted quarterly Amortizatization of Intangibles of $1.0 for Q2 2019, down 100.0% year-over-year from $527980.0 in Q2 2018, and down 100.0% quarter-over-quarter from $124647.0 in Q4 2018.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Amortizatization of Intangibles (2014 - 2019) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Amortizatization of Intangibles for 4 consecutive years, with $1.0 the latest figure, recorded in Q2 2019.
- In Q2 2019, Amortizatization of Intangibles fell 100.0% year-over-year to $1.0; the TTM figure through Jun 2019 stood at $661168.0 (down 35.76% YoY), while the FY2019 annual figure was $661168.0, down 35.76% from the prior year.
- Amortizatization of Intangibles slipped to $1.0 in Q2 2019 per RLMD's latest filing, from $124647.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $536520.0 in Q3 2018 and bottomed at $1.0 in Q2 2019.
- Historically, Amortizatization of Intangibles has averaged $241478.7 across 3 years, with a median of $204962.0 in 2017.
- Annual changes were most pronounced in 2018 — Amortizatization of Intangibles jumped 18932.28% — and 2019, when it slumped 100.0%.
- Relmada Therapeutics' Amortizatization of Intangibles stood at $204962.0 in 2017, then sank by 39.19% to $124647.0 in 2018, then plunged by 100.0% to $1.0 in 2019.
- Business Quant data shows RLMD's Amortizatization of Intangibles at $1.0 in Q2 2019, $124647.0 in Q4 2018, and $536520.0 in Q3 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2019 | 1.00 |
| Dec 31, 2018 | 124,647.00 |
| Sep 30, 2018 | 536,520.00 |
| Jun 30, 2018 | 527,980.00 |
| Mar 31, 2018 | 293,422.00 |
| Dec 31, 2017 | 204,962.00 |
| Sep 30, 2017 | 2,819.00 |
| Jun 30, 2014 | 327,776.00 |
| Mar 31, 2014 | 172,818.00 |